



Innovating for patients

GRIFOLS

Innovating for patients

Press Kit 2024

© of texts and photographs: Grifols S.A.

All rights reserved. Any form of reproduction or publication of this work, in any medium, even if quoted, is prohibited without the prior written consent of the authors.




Caring for People

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Our unique and remarkable history combines scientific expertise with a desire to serve patients and society.

We are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.



Grifols at a glance


800,000+
PATIENTS
treated in 2023


PRODUCTS AND
SERVICES IN
110+
COUNTRIES & REGIONS


€6.6 BN
REVENUES IN 2023


920,000
DONORS
in 2023


LARGEST NETWORK OF DONATION
CENTERS IN THE WORLD
390+


23,000+
EMPLOYEES

Our business units



Biopharma

Dedicated to plasma procurement as well as the development, production and commercialization of plasma and non-plasma solutions to treat patients with chronic and rare diseases that can be life-threatening.



Diagnostic

Transfusion medicine solutions to ensure blood compatibility and detect possible pathogens in donors while also simplifying laboratory operations, as well as clinical diagnostic solutions.



Bio Supplies

Providing high-quality biological materials from our plasma and blood donation centers for research in life sciences, clinical trials as well as for pharmaceutical and diagnostic manufacturing.



Healthcare Solutions for Hospitals

Serving the needs of hospital pharmacies, through intravenous solutions, high-tech solutions, clinical nutrition and medical devices.



JOSEP ANTONI GRIFOLS I ROIG AND VÍCTOR GRÍFOLS I LUCÁS IN THE RAMBLA DE CATALUNYA ANALYSIS LABORATORY (BARCELONA, SPAIN), 1930S

From family business to global company

Grifols' growth during more than a century has been a story of dedication, innovation and a unique vision.

Founded in 1909 as a small, family-run clinical analysis laboratory in Barcelona, the company gained momentum as it embraced industrialization, then accelerated exponentially as a world-spanning multinational.

Today, Grifols has subsidiaries in more than 30 countries and regions and a global team of more than 23,000 people.

Throughout these past 115 years and with the unwavering commitment from four different generations of the Grifols family, the company has strived to generate positive social impact to create a better society for all. This legacy has shaped who we are today and how we keep working to bring our medicines to more patients in more parts of the world.



JOSEP ANTONI GRIFOLS I LUCAS AND EDWIN J. COHN AT THE 4TH INTERNATIONAL BLOOD TRANSFUSION CONGRESS IN PORTUGAL, IN 1951.

Grifols, a success story

Our unique and remarkable history combines scientific expertise with a desire to serve patients and society. We owe our success to the vision and perseverance of the company's founder, Josep Antoni Grifols i Roig, his sons Josep Antoni and Víctor, and all those who have followed in their footsteps. Grifols' key milestones are outlined below.



Josep Antoni Grifols i Roig (1886-1976)



Josep Antoni Grifols i Lucas (1917-1958)



Víctor Grifols i Lucas (1919-2015)



Victor Grifols Roura



Víctor Grifols Deu and Raimon Grifols

1909

Josep Antoni Grifols i Roig establishes the Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos, a precursor to Laboratorios Grifols.

1928

Grifols i Roig patents the first instrument for carrying out indirect blood transfusions in Spain, the transfusion flebula.



1943

Grifols introduces into Spain the freeze-drying process to expand the shelf-life of human plasma.

1945

The Hemobanco, first private blood and plasma bank in Spain, opens its doors in Barcelona.

1951

Josep Antoni Grifols i Lucas develops the plasmapheresis technique, which continues to be the gold standard of care for plasma collection globally.



The company Gri-Cel, dedicated to the design and manufacture of scientific instruments and reagents for blood banks, is founded.

1958

Grifols opens its first plasma fractionation department in Barcelona.

1960

Dade-Grifols is founded as a result of the association with the North American company Dade Reagents - Grifols' first international partner - to import diagnostic reagents.

1972

The first plasma fractionation plant starts operations in Parets del Vallès, Barcelona.



1987

The holding company Grupo Grifols is created.

1988


International expansion begins with the first subsidiary in Portugal.

1995

Grifols becomes the first Spanish company to receive a license from the U.S. FDA for its facilities and for a biological product, albumin.

2006

Grifols begins trading on the Spanish Stock Exchange.



2011

With the acquisition of Talecris Biotherapeutics, Grifols becomes the third-largest manufacturer of plasma-derived medicines in the world and begins trading on the New York City-based NASDAQ.

2014

Grifols acquires Novartis' transfusion diagnostics unit.

2017

With the acquisition of Hologic's transfusion diagnostics unit, Grifols researches, develops and produces reagents and instrumentation based on NAT (nucleic acid detection) technology.

2020

Grifols and Shanghai RAAS form a strategic alliance.



Grifols and the Egyptian government sign a joint venture to develop the first integrated plasma supply platform in Egypt and the region to facilitate self-sufficiency.

Grifols acquires Alkahest, a U.S. clinical-stage biopharmaceutical company focused on neurodegenerative and age-related diseases.

2021

Grifols acquires GigaGen, a U.S. biotechnology company specialized in early discovery and the development of recombinant biotherapeutic medicines.

2022

Grifols joins forces with Biotest, a European leader in plasma-derived medicines with a strong pipeline of complementary innovation.

Grifols and Canadian Blood Services sign a pioneering long-term agreement to increase the country's self-sufficiency in immunoglobulin medicines.

2023

Grifols signs a strategic alliance with Haier Group to contribute to China's growing and developing healthcare system.



A Global Plasma Powerhouse

Grifols is the third-largest global producer of plasma-derived medicines and other innovative therapies for the treatment of rare, chronic and sometimes life-threatening conditions.

The production of biological medicines is a process unlike any other in the pharmaceutical industry. Plasma-derived medicines require a lengthy and complex manufacturing process, taking up to 12 months from the moment a person donates plasma until the time when the final medicinal product is ready to be administered, all while going through a rigorous system of industry-leading quality and safety measures.

Our global manufacturing facilities utilize state-of-the-art methods and production processes designed by Grifols Engineering, renowned globally for its innovation and excellence.

Grifols is also helping countries and healthcare systems around the world become self-sufficient in plasma-derived medicines by forging innovative public-private alliances.



Plasma proteins and our key therapeutic areas

Plasma is a limited biological resource available only through voluntary donations – it cannot be produced in a laboratory. Oftentimes a plasma therapeutic is the only viable treatment option, making it even more special.



Immunology

Immunoglobulins

Treatment of primary and secondary immunodeficiencies and autoimmune diseases.



Pulmonology

Alpha-1 antitrypsin

Treatment of alpha-1 antitrypsin deficiency, which can lead to serious lung disorders such as emphysema.



Neurology

Immunoglobulins

Treatment of rare autoimmune neurological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP).



Hepatology and Intensive care

Albumin

Restoration of circulatory volume and protein loss in liver cirrhosis, cardiocirculatory failure, trauma or severe burns.



Hematology

Coagulation factors Fibrinogen

Treatment of coagulation disorders such as hemophilia and von Willebrand's disease, as well as for the control of bleeding in surgery.



Infectious diseases

Hyperimmune Immunoglobulins

Treatment of infections such as rabies, tetanus, hepatitis A and hepatitis B.

Industrial footprint and Engineering know-how



16 production plants


(two other plants being built in Canada and Egypt)



22M liters/year

FRACTIONATION CAPACITY aiming to reach 26M by 2026

Grifols Engineering designs and builds the company's global production facilities, machinery and robotic systems with the highest standards of excellence, quality and safety. Our expertise and know-how are the result of several decades of developing in-house processes and facility projects. Grifols Engineering also offers its technology and consulting services to the pharmaceutical and biotechnology sectors.



Grifols Global Plasma Self-sufficiency Program



Our commitment to help countries become self-sufficient in plasma-derived medicines has brought us to reach alliances with public systems around the world.

Grifols Egypt for Plasma Derivatives is the joint venture that we established with the Egyptian government to build the first integrated platform for sourcing and producing plasma medicines in Egypt and the wider region.

The company also has a long-term agreement with **Canadian Blood Services**, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines.



Scientific Innovation

Since its inception, Grifols has been at the forefront of healthcare innovation, driven by a commitment to advancing global health and the well-being of patients.

Our ever-growing knowledge of the causes of many chronic, rare and prevalent diseases is driving the development of potential new treatment options derived both from our expertise in human plasma as well as a new class of recombinant antibody drugs.

We probe deeply into a range of pathologies – from immunodeficiencies to respiratory disorders to age-related conditions – to create innovative therapeutics that adhere to the highest scientific, ethical and quality standards to help improve people's lives.

Today, innovation continues to be an investment priority and is the company's growth engine.



Key innovation figures

Our innovation hubs

California Hub
Emeryville
San Carlos
Los Angeles
San Diego
South San Francisco

North Carolina Hub
Research Triangle Park

European Hub
Barcelona (ES)
Dreieich* (DE)
Dublin (IR)
Düdingen (CH)
Bilbao (ES)
Zaragoza (ES)

Shanghai RAAS
Shanghai (CN)



13

R&D+I CENTERS



1,200+

RESEARCHERS



€1.7B

INVESTMENT IN
THE LAST 5 YEARS



2,705

PATENTS

*Biotest

Continuous improvement of plasma treatments



Biologics derived from plasma are a fundamental part of Grifols innovation pipeline.

The company is working to identify new proteins with therapeutic value from the plasma proteome (the known universe of all plasma proteins) and also new therapeutic targets for existing plasma-derived medicines including immunoglobulins, alpha-1 proteinase inhibitor, fibrinogen, albumin and antithrombin-III.

Beyond plasma:

Innovations in biomedical therapies and diagnostics

Grifols is expanding its range of therapeutic options to include innovative polyclonal antibody therapies as well as novel monoclonal antibodies. The company's goal to expand its therapeutic reach also includes investment in industry-leading technology platforms and products through key partnerships and acquisitions, such as GigaGen, Alkahest or Araclon. Our Diagnostic unit also researches and develops innovative solutions for blood and plasma donor screening, as well as clinical diagnosis of diseases.





Contributing to society

Grifols' commitment to improve social health and well-being goes beyond the company's industrial activity. We strive to leave a positive impact both on people and the planet.

This long-term commitment, which reflects the company's corporate values, is our response to the needs of patients, donors, local communities and society as a whole.



“The right to live in society entails the duty to work to improve it.”

Josep Antoni Grífols i Roig, founder

We channel our social efforts throughout our three foundations

Fundació Víctor Grífols i Lucas

Promotes dialogue and transdisciplinary research on the bioethical issues that affect society and the delivery of healthcare.



Fundación Probitas

Supports programs and initiatives in several developing countries. It allocates funding to projects aimed at improving access to healthcare in populations where resources are scarce.



J.A. Grifols Foundation

Provides educational and health grants that enhance the quality of life in communities where our plasma donation centers are located.



 **23.5M €**
TOTAL SOCIAL CONTRIBUTIONS
IN 2023

Grifols, recognized as one of the most sustainable companies in the world

At the end of 2023, the company was included in the Dow Jones Sustainability Indices (DJSI) for the fourth consecutive year, reflecting the company's ongoing commitment to environmental, social and governance (ESG) leadership.

S&P Dow Jones Indices

A Division of **S&P Global**

GRIFOLS